@AllAroundA1 It's obvious they are threatened by you. You literally came on and swept the scene. Be flattered but I feel you for responding how you respond.
i shorted $OPEN today at 9.36.
this is the first trade i've made in the stock. i will be doing diligence calls with former employees, customers, competitors and hopefully, management too! i will send invites to the calls or anonymous transcripts as appropriate.
@dani__spx7 I've been told by so many who been in been in the game to wait until 15 or 39 min ORG. OR wait until first hour. I'm starting to not believe that ! Seen to many screen shots of gains within the first hour.
Love to see the pressure on $open to succeed but let’s be real: Carrie isn’t stepping down and Eric isn’t being invited to the board. Saying something like you have until the 20th is childish.
@ericjackson With the disrespect and personal attacks on @carriecwheeler I hope she tells you to go fuck yourself . She doesn’t need to speak to you. Here you go making it about you again lol
Dopamine is a hell of a drug. Eric Jackson will dump his shares the moment he isn’t center of attention and hurt a ton of retail investors if he doesn’t get his way. $Open
Love to see the pressure on $open to succeed but let’s be real: Carrie isn’t stepping down and Eric isn’t being invited to the board. Saying something like you have until the 20th is childish.
Morgan Stanley initiates coverage on Hims & Hers Health $HIMS with a Buy and Price Target of $42 (+30%)
The firm views Hims & Hers as a "compelling compounding investment" and estimates annual revenue growth of 30% through 2026, "building on very strong growth" of 80% per annum in the last three years. The company has established itself with one of the stronger track records spanning the domains of digital health and direct-to-consumer. Morgan Stanley believes Hims & Hers has a scalable technology platform.